Therapeutic Antibody Development Services
Therapeutic antibodies used for brain tumors are specially engineered proteins designed to selectively recognize and bind to specific antigens present on the surface of brain tumor cells. These antibodies can block growth signals in tumor cells, induce apoptosis, or recruit the immune system to attack tumor cells, thereby achieving therapeutic purposes. Alfa Cytology is actively engaged in cutting-edge research and development of therapeutic antibodies targeting brain tumors, assisting clients in developing more effective and safer treatment methods.
Overview of Therapeutic Antibody
Therapeutic antibodies for brain tumors are an innovative class of treatments that offer targeted intervention against malignant cells within the brain. These engineered antibodies are designed to specifically recognize and bind to antigens that are uniquely expressed or overexpressed on the surface of brain tumor cells. By binding to these targets, the antibodies can inhibit tumor growth pathways, induce cancer cell death (apoptosis), or recruit the body’s immune system to attack the tumor cells.
Fig 1. Antibodies can cross the blood-brain barrier to treat brain tumors. (EDAVETTAL S, et al., 2022)
Therapeutic Antibody Development for Brain Tumors
| Company |
Targets |
Name |
Molecule Type |
Phase |
| Y-mAbs Therapeutics |
GD2 |
Naxitamab |
Antibody |
|
| Vaccinex |
SEMA4D |
Pepinemab |
Antibody |
|
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Leveraging its deep expertise and technological strengths in the field of cancer therapy, Alfa Cytology offers comprehensive services from target identification to drug development, including the development of antibody drugs for brain tumors. With an experienced team of scientists, the company provides personalized collaboration plans for clients, aiding in advancing the research and development process of brain tumor antibody drugs.
Monoclonal Antibody
Developing monoclonal antibodies that specifically target antigens expressed on brain tumor cells. These antibodies offer precise therapy by binding exclusively to tumor cells, potentially improving treatment efficacy and reducing side effects.
Bispecific Antibody
Creating bispecific antibodies that can simultaneously bind to two different antigens, such as a tumor antigen and an immune cell receptor. This dual-binding approach enhances the immune system's ability to recognize and attack brain tumor cells more effectively.
Polyclonal Antibody
Producing polyclonal antibodies that recognize multiple epitopes on brain tumor cells. This broad-spectrum antibody response can address tumor heterogeneity, potentially leading to more comprehensive tumor targeting.
Multispecific Antibody
A multispecific antibody is an engineered antibody designed to simultaneously bind to two or more different antigens or epitopes, enhancing therapeutic efficacy by engaging multiple targets at once.
Antibody Fragment
An antibody fragment is a portion of an antibody molecule (such as Fab, F(ab')2, or scFv) that retains the antigen-binding capability but is smaller than a full-length antibody, allowing for better tissue penetration and reduced immunogenicity.
Antibody-Drug Conjugates (ADC)
Developing antibody-drug conjugates (ADCs) by linking cytotoxic drugs to antibodies specific for brain tumor antigens. ADCs deliver potent anti-cancer drugs directly to tumor cells, maximizing therapeutic effects while minimizing damage to healthy tissue.
Antibody-Toxin Conjugate (ATC)
Creating antibody-toxin conjugates (ATCs) by coupling toxins with antibodies that target brain tumor cells. This targeted delivery system aims to introduce toxins directly into tumor cells, inducing cell death and offering a highly specific treatment option.
More
Alfa Cytology also offers a variety of other antibody services to support your research and development needs. From custom antibody production to antibody optimization and modification, our comprehensive solutions are designed to aid in the discovery and development of cancer therapeutics.
Alfa Cytology offers clients comprehensive, one-stop development services for brain tumor antibody drugs-including target discovery, antibody screening and optimization, drug development, and preclinical research. If you encounter any issues or have any questions during your project, please feel free to
contact us; we are committed to providing you with full support and assistance.
Reference
- EDAVETTAL S, CEJUDO-MARTIN P, DASGUPTA B, et al. Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis [J]. Med, 2022, 3(12): 860-82.e15.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
